Sarepta Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Sarepta is a commercial-stage biopharmaceutical company developing RNA-targeted therapeutics, gene therapies and other genetic medicines for rare diseases. Its commercial products are EXONDYS 51, VYONDYS 53 and AMONDYS 45 for Duchenne muscular dystrophy. This unaudited filing covers the three months ended March 31, 2023, compared with the three months ended March 31, 2022.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $253.5 million | $210.8 million | 20% increase |
| Product revenue | $231.5 million | $188.8 million | 23% increase |
| Collaboration revenue | $22.0 million | $22.0 million | No change |
| Operating loss | $138.1 million | $86.9 million | 59% larger loss |
| Net loss | $516.8 million | $105.0 million | $411.7 million larger loss |
| Net loss per share | $5.86 | $1.20 | Higher loss per share |
| Cash used in operating activities | $209.4 million | $101.2 million | $108.2 million higher use |
Reported cost of sales, including amortization of in-licensed rights, was approximately $35.2 million, implying gross profit of approximately $218.3 million and a gross margin of approximately 86.1%. The operating margin was approximately negative 54.5%, and the net margin was approximately negative 203.9%; the net margin was significantly affected by the $387.3 million loss on extinguishment of debt.
Product revenue growth primarily reflected increased demand: EXONDYS 51 revenue was $132.6 million, AMONDYS 45 revenue was $65.9 million and VYONDYS 53 revenue was $33.0 million. U.S. product revenue was $200.5 million, or more than 85% of product revenue. Three customers accounted for 49%, 32% and 7% of product revenue.
Research and development expense increased 26% to $245.7 million, principally due to SRP-9001 manufacturing, higher personnel costs, clinical-trial activity and preparation for a potential SRP-9001 launch. Selling, general and administrative expense increased 54% to $110.7 million, driven by personnel, professional services, commercialization preparation and stock-based compensation.
As of March 31, 2023, Sarepta had $871.7 million of cash and cash equivalents, $1.010 billion of short-term investments and $19.0 million of restricted cash, totaling approximately $1.901 billion of cash, cash equivalents, restricted cash and investments. Total debt carrying value was $1.234 billion, consisting primarily of $1.150 billion principal of 2027 convertible notes and approximately $105.8 million principal remaining on the 2024 notes. Management stated that available liquidity was sufficient to fund its current operating plan for at least the next twelve months.
Material changes versus the prior comparable period
- Product revenue increased $42.7 million, or 23%, while collaboration revenue remained $22.0 million.
- Operating expenses increased $93.9 million, or 32%, outpacing revenue growth.
- The March 2023 exchange of $313.5 million principal amount of 2024 notes for approximately 4.5 million common shares reduced debt by approximately $310.0 million but generated a $387.3 million accounting loss on extinguishment.
- The debt exchange and related capped-call settlement resulted in approximately $80.6 million of cash proceeds and increased common shares outstanding to approximately 93.1 million at March 31, 2023, from approximately 88.0 million at December 31, 2022.
- Operating cash use more than doubled year over year, partly reflecting a $54.0 million payment to Thermo, higher manufacturing prepayments, increased receivables and reduced accrued liabilities.
- Cash provided by investing activities was $12.5 million, compared with $785.8 million used in the prior-year quarter, reflecting maturities and sales of investments exceeding purchases.
Guidance, outlook, risks and unusual items
The filing does not provide a clear numerical revenue or earnings forecast. Management expects continued significant operating losses at least through 2023 and expects future capital needs to depend on development, regulatory and commercialization activities.
The FDA’s anticipated action date for the SRP-9001 biologics license application was May 29, 2023, with an advisory committee meeting scheduled for May 12, 2023. Sarepta also planned to engage with the FDA regarding SRP-9003 during 2023 and completed enrollment of Part B of the SRP-5051 study in the first quarter.
Key risks include the accelerated-approval requirements for the three commercial products, the need to verify clinical benefit in confirmatory trials, uncertain regulatory outcomes for SRP-9001 and other candidates, manufacturing and supply-chain dependence on third parties, customer and U.S. revenue concentration, reimbursement and pricing pressure, competition, intellectual-property litigation, and potential delays or adverse results in clinical trials.
Sarepta reported approximately $1.369 billion of manufacturing commitments as of March 31, 2023. It may also owe up to $3.1 billion of future development, regulatory, commercial and royalty milestone payments under license and collaboration agreements, generally contingent on successful milestones. The company disclosed patent litigation involving RegenXBIO and the University of Pennsylvania concerning SRP-9001, and litigation involving Nippon Shinyaku concerning exon-53 technology; no material loss accrual was recorded and management stated that no material loss range was estimable.
In March 2023, Sarepta amended its Thermo manufacturing agreement, removing a prior $54.7 million annual minimum purchase commitment and replacing it with potential payments of up to $60.0 million through 2025, subject to specified waivers. The filing also disclosed product batch write-offs in cost of sales and $41.3 million of stock-based compensation expense.
Facts investors should verify
- Outcome and commercial implications of the FDA review and advisory committee process for SRP-9001.
- Progress and results of confirmatory and post-marketing studies supporting the accelerated approvals of EXONDYS 51, VYONDYS 53 and AMONDYS 45.
- Whether product revenue growth can offset rising research, manufacturing, commercialization and administrative costs.
- Cash burn, liquidity runway and the company’s ability to fund approximately $1.4 billion of manufacturing commitments and scheduled debt obligations.
- Potential dilution from convertible notes, outstanding equity awards and future financing needs.
- Manufacturing capacity, product quality and supply availability for SRP-9001 and existing commercial products.
- Developments in the RegenXBIO/University of Pennsylvania and Nippon Shinyaku litigation and their potential effects on commercialization.
- Customer concentration, reimbursement trends and the expiration or challenge of regulatory and patent exclusivity, including the expected September 2023 end of EXONDYS 51 orphan exclusivity.